Dr. C. Michael Stein is a co-investigator on the Vanderbilt Pharmacogenetics initiative where he is studying genetic contributions to variability in response to warfarin, and alpha and beta adrenergic receptor agonists and antagonists.

His research interests include the regulation of vascular response by genetic and environmental factors, genetic basis of interindividual variability in drug response and the relationship between atherosclerosis and inflammation.

His research spans clinical and bridges cardiology, rheumatology and clinical pharmacology. These initiatives use many techniques including plethysmography, hand vein reactivity, norepinephrine spillover, flow-mediated dilation using ultrasound and electron beam CT to study the regulation of vascular response in health and disease. He has active, funded programs in rheumatology that address the relationship between disease activity, oxidative stress and atherosclerosis in patients with SLE and RA.

He is also an investigator on the Centers for Education and Research in Therapeutics (CERTS) program which uses pharmacoepidemiology tools to study the cardiovascular and GI effects of COX-2 selective NSAIDs.

Complete Information